Home/ Stocks/ CPRX

Catalyst Pharmaceutical Inc.

CPRX XNAS

$31.15 -0.09 (-0.27%) ▼ 15-min delayed

Open

$31.14

High

$31.21

Low

$31.13

Volume

4.48M

Market Cap

$3.81B

About Catalyst Pharmaceutical Inc.

Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 182 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$588.99M	$214.33M	$1.75
FY 2025	$588.99M	$214.33M	$1.75
Q3 2025	$148.39M	$52.78M	$0.43
Q2 2025	$146.56M	$52.11M	$0.43

Earnings & Analyst Ratings

Next Earnings: Tue, Aug 4, 2026

Calendar →

Related Market News

No specific coverage for CPRX yet. Check out our latest market news or earnings calendar.

Get CPRX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Catalyst Pharmaceutical Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.